Insulet (NASDAQ:PODD) PT Raised to $223.00

Insulet (NASDAQ:PODD) had its price objective upped by equities research analysts at UBS Group from $211.00 to $223.00 in a report released on Friday, Benzinga reports. The firm presently has a “neutral” rating on the medical instruments supplier’s stock. UBS Group’s price objective suggests a potential upside of 22.40% from the company’s current price.

A number of other equities analysts have also recently commented on PODD. Raymond James reduced their price target on Insulet from $218.00 to $213.00 and set an “outperform” rating for the company in a report on Friday, May 10th. Barclays reduced their target price on Insulet from $213.00 to $200.00 and set an “equal weight” rating for the company in a research note on Monday, May 13th. Redburn Atlantic began coverage on Insulet in a research note on Thursday, May 30th. They issued a “buy” rating and a $235.00 price target on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $234.00 price objective on shares of Insulet in a research report on Tuesday, July 23rd. Finally, OTR Global reissued a “mixed” rating on shares of Insulet in a research report on Monday, June 10th. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $230.88.

Insulet Stock Down 8.8 %

Shares of Insulet stock traded down $17.60 during trading on Friday, reaching $182.19. The stock had a trading volume of 2,129,777 shares, compared to its average volume of 672,840. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72. The company has a market capitalization of $12.76 billion, a price-to-earnings ratio of 55.21, a P/E/G ratio of 3.53 and a beta of 1.16. The stock has a fifty day moving average price of $196.26 and a two-hundred day moving average price of $183.90. Insulet has a 52 week low of $125.82 and a 52 week high of $239.70.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.02). The firm had revenue of $488.50 million during the quarter, compared to the consensus estimate of $488.00 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. Insulet’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.38 earnings per share. Sell-side analysts predict that Insulet will post 3.11 EPS for the current fiscal year.

Insider Activity at Insulet

In other Insulet news, SVP Mark N. Field sold 2,131 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $190.43, for a total transaction of $405,806.33. Following the transaction, the senior vice president now owns 14,375 shares in the company, valued at approximately $2,737,431.25. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, SVP Mark N. Field sold 2,131 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $190.43, for a total value of $405,806.33. Following the transaction, the senior vice president now owns 14,375 shares in the company, valued at $2,737,431.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mark N. Field sold 1,500 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $199.96, for a total value of $299,940.00. Following the completion of the transaction, the senior vice president now directly owns 12,875 shares of the company’s stock, valued at approximately $2,574,485. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,931 shares of company stock worth $2,636,286. Company insiders own 0.47% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Consolidated Portfolio Review Corp lifted its stake in Insulet by 1.6% during the fourth quarter. Consolidated Portfolio Review Corp now owns 3,713 shares of the medical instruments supplier’s stock worth $806,000 after purchasing an additional 57 shares during the last quarter. FourThought Financial Partners LLC grew its position in Insulet by 1.4% in the fourth quarter. FourThought Financial Partners LLC now owns 4,461 shares of the medical instruments supplier’s stock valued at $968,000 after acquiring an additional 61 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Insulet by 1.1% during the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,265 shares of the medical instruments supplier’s stock worth $1,264,000 after acquiring an additional 66 shares in the last quarter. Linden Thomas Advisory Services LLC lifted its holdings in shares of Insulet by 1.3% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 5,817 shares of the medical instruments supplier’s stock worth $1,262,000 after acquiring an additional 73 shares during the last quarter. Finally, Lindbrook Capital LLC boosted its stake in shares of Insulet by 64.1% in the 4th quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock valued at $42,000 after purchasing an additional 75 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.